The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1489-1496

  Piechnik, Agnieszka ^a   Dmoszynska, Anna ^a   Omiotek, Marcin ^a   Mlak, Radosław ^a   Kowal, Małgorzata ^a   Stilgenbauer, Stephan ^b   Bullinger, Lars ^b   Giannopoulos, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

chronic lymphocytic leukemia; neuropilin 1; vascular endothelial growth factor

Indexed keywords

CD38 ANTIGEN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; NEUROPILIN 1; PROTEIN KINASE ZAP 70; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL SUBPOPULATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE;

CHRONIC LYMPHOCYTIC LEUKEMIA; NEUROPILIN-1; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; AGED; AGED, 80 AND OVER; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879991337     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28135     Document Type: Article

References (32)

1. Dighiero D, Travade P, Chevret S, et al. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 1991; 78: 1901-14.
2. Folkman J, Shing Y,. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
3. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 293-312.
4. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Path 1995; 5: 1029-40.
5. Ferrara N, Gerber HP, Le Couter J,. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-79.
6. Berns EM, Klijn JG, Look MP, et al. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 2003; 9: 1253-8.
7. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (Flt-1) in nephroblastoma. J Clin Pathol 2003; 56: 107-113.
8. Zielger BL, Valtieri M, Porada Almeida G, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science 1999; 285: 1553-8.
9. Sun JG, Wang Y, Chen ZT, et al. Detection of lymphangiogenesis in non-small cell lung cancer and its prognostic value. J Exp Clin Cancer Res 2009; 28: 21.
10. Schuch G, Machluf M, Bartsch GJ, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002; 100: 4622-8.
11. Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-31.
12. Gõra-Tabor J, Błoński JZ, Robak T,. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw 2005; 16: 41-6.
13. Fujimoto K, Hosotani R, Wada M, et al. Expression of two angiogenetic factors, vascular endothelial growth factor and platelet- derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998; 34: 1439-47.
14. Frater JL, Kay NE, Goolsby CL, et al. Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical and flow cytometric evidence. Diagn Path 2008; 3: 1-10.
15. Aguayo A, Manshouir T, O'Brien S, et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res 2001; 25: 279-85.
16. Romeo PH, Lemarchandel V, Tordjman R,. Neuropilin-1 in the immune system. Adv Exp Med Biol 2002; 515: 49-54.
17. Gutmann-Raviv N, Kessler O, Shraga-Heled N, et al. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett 2006; 231: 1-11.
18. Nowakowski GS, Mukhopadhay D, Wu X, et al. Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells. Leuk Res 2008; 32: 1634-6.
19. Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008; 28: 402-413.
20. Giannopoulos K, Dmoszynska A, Kowal M, et al. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009; 23: 1771-8.
21. Pan Q, Chanthery Y, Liang WC, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007; 11: 53-67.
22. Latil A, Bièche I, Pesche S, et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 2000; 89: 167-71.
23. Lantuéjoul S, Constantin B, Drabkin H, et al. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003; 200: 336-47.
24. Parikh AA, Fan F, Liu WB, et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004; 164: 2139-51.
25. Lu L, Zhang L, Xiao Z, et al. Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma 2008; 49: 331-8.
26. Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002; 3: 477-82.
27. Sakaguchi S, Wing K, Miyara M,. Regulatory T cells-a brief history and perspective. Eur J Immunol 2007; 37: 116-23.
28. Beyer M, Schultze JL,. Regulatory T cells in cancer. Blood 2006; 108: 804-11.
29. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20: 677-82.
30. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-25.
31. Giannopoulos K, Schmitt M, Wlasiuk P, et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22: 222-4.
32. Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010; 148: 948-96. Education